Search results
Results from the WOW.Com Content Network
904,000 (2015) [6] Deaths. 60,700 (2015) [7] Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). [2][8] Early on, there are typically no symptoms. [2] Later, non-painful lymph node swelling, feeling tired, fever, night sweats, or weight loss for no clear reason ...
CLL/SLL is the most common adult leukemia in Western countries, accounting for 1.2% of the new cancers diagnosed each year in the United States. It usually occurs in older adults (median age at diagnosis 70) and follows an indolent course over many years. [11] About 1-10% of CLL/SLLs develop a Richter's transformation at a rate of 0.5–1% per ...
Treatment can occasionally consist of "watchful waiting" (e.g., in CLL) or symptomatic treatment (e.g., blood transfusions in MDS). The more aggressive forms of disease require treatment with chemotherapy, radiotherapy, immunotherapy and—in some cases—a bone marrow transplant.
For premium support please call: 800-290-4726 more ways to reach us
Leukemia (also spelled leukaemia; pronounced / luːˈkiːmiːə / [1] loo-KEE-mee-ə) is a group of blood cancers that usually begin in the bone marrow and produce high numbers of abnormal blood cells. [9] These blood cells are not fully developed and are called blasts or leukemia cells. [2]
592. Website. www.consumerreports.org. Consumer Reports (CR), formerly Consumers Union (CU), is an American nonprofit consumer organization dedicated to independent product testing, investigative journalism, consumer-oriented research, public education, and consumer advocacy. [2] Founded in 1936, CR was created to serve as a source of ...
NK cell leukemia. Aggressive NK-cell leukemia (ANKL) is a lymphoid leukemia that is a deficiency NK cells. Not very much is known about this disease due to its rarity, but it is highly aggressive. A majority of patients with NK cell leukemia die within a year of diagnosis, and for ANKL in particular, half of patients die within two months.
Alemtuzumab. Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. [8] In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. [8] It is given by injection into a vein.